SafeBridge Consultants, Inc. Announces Availability of Computational Predictive Toxicology Capabilities
January 07, 2014
SAFEBRIDGE® CONSULTANTS, INC. ("SafeBridge"), a division of Trinity Consultants, Inc., Dallas, TX, with offices in Mountain View, CA, New York, NY, and Liverpool, UK, announces the availability of computational predictive toxicology services to the biopharmaceutical and chemical industry. With increasing numbers of potential chemical impurities in drugs, foods, cosmetics and consumer products, computational tools have become an integral part of safety assessment and enable higher throughput and successful risk prioritization strategies.
SafeBridge is an authorized user of Derek Nexus from Lhasa Ltd. of Leeds, UK, a knowledge-based expert system for the prediction of toxicological hazard, and Leadscope® Model Applier from Leadscope, Inc. of Columbus, Ohio, a statistical predictive quantitative structure-activity relationships (“QSAR”) model.
SafeBridge will be able to apply these two software packages to:
- Assist pharmaceutical and chemical companies to meet the proposed International Conference on Harmonization (“ICH”) M7 “Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk” guideline;
- Conduct risk assessments of extractable and leachable chemicals into drug products;
- Assess the potential toxicity of contaminants in drugs, cosmetics, and other products for endpoints such as sensitization, nephrotoxicity, and reproductive effects; and
- Assist in chemical synthetic process development
SAFEBRIDGE CONSULTANTS, INC. is the premier occupational health and safety and risk assessment consulting firm to the pharmaceutical, biotechnology, and fine chemical industry. The SafeBridge staff of Ph.D.-level toxicologists has provided risk assessment services in occupational toxicology and product safety to over 600 companies worldwide. SafeBridge provides the Potent Compound Safety Triangle® of services in industrial hygiene, occupational toxicology, and analytical chemistry and is the leader in recognizing, evaluating, and controlling exposures to potent active pharmaceutical ingredients and products.
For more information, contact:
John P. Farris, CIH
President and Chief Executive Officer
650-961-4820 x 229